By The Life Science Report
Source: Streetwise Reports 04/11/2018
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts.
An April 10 research note issued by Laidlaw & Co. reported that Therapix Biosciences Ltd.’s (TRPX:NASDAQ; THXBY:TASE) TXH-110 “significantly (p=0.002) improved symptoms over time” in patients with refractory Tourette syndrome, wrote analyst Francois Brisebois. “The entourage effect passes with flying colors.” THX-100 is comprised of dronabinol, a biosynthetic THC, and palmitoylethanolamide, or PEA.
Specifically, data from this investigator-initiated Phase 2a study, showed that with THX-100, the occurrence of tic symptoms in patients dropped to 7.9 from a baseline of 38.4, using the Yale Global Tic Severity-Total Tic Score. Six of 16 patients experienced a score reduction of greater than 25%. “We are especially encouraged as most of these patients (n=16) had severe, refractory Tourette syndrome and hadn’t responded to any other treatment (antipsychotics, alpha-2 agonists, behavioral therapy) or other investigational compounds,” Brisebois noted.
Another encouraging factor, Brisebois pointed out, is THX-100’s safety profile. Only two patients curtailed treatment early due to feeling sedated and not experiencing improvement in tic symptoms. “We also see as a significant positive the fact that 12 of 16 patients chose to continue into a 24-week extension,” he added.
Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
As for upcoming catalysts, several are on the horizon for Therapix this year, Brisebois indicated. First, results from this Phase 2a trial in Tourette syndrome will be presented in full at the 2018 European Society for the Study of Tourette Syndrome meeting in June.
Late in Q2/18, a subsequent Phase 2b randomized, double-blind, placebo-controlled study of THX-100 in Tourette syndrome will begin. Data from it are expected in 2019.
Toward Q4/18, results are expected from Phase 2a trials of THX-100 in obstructive sleep apnea and chronic lower back pain.
Laidlaw maintains its Buy rating and $18 per share price target on Therapix, whose stock is currently trading at $4.93 per share.
Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you’ll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Disclosures from Laidlaw & Co., Therapix Biosciences, Company Report, April 10, 2018
ANALYST CERTIFICATION The analyst responsible for the content of this report hereby certifies that the views expressed regarding the company or companies and their securities accurately represent his personal views and that no direct or indirect compensation is to be received by the analyst for any specific recommendation or views contained in this report. Neither the author of this report nor any member of his immediate family or household maintains a position in the securities mentioned in this report.
Laidlaw & Company has received compensation from the subject company for investment banking services in the past 12 months and expects to receive or intends to seek compensation for investment banking services from the company in the next three months.
As of the date of this report, neither the author of this report nor any member of his immediate family or household maintains an ownership position in the securities of the company (ies) mentioned in this report.
Associated persons of Laidlaw & Co (UK), Ltd not involved in the preparation of this report may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned herein and may trade them in ways different from those discussed in this report. While Laidlaw & Co (UK), Ltd., prohibits analysts from receiving any compensation. Bonus or incentive based on specific recommendations for, or view of, a particular company, investors should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.
( Companies Mentioned: TRPX:NASDAQ; THXBY:TASE,